Table 5

Change in daytime somnolence, health-related quality of life and anxiety and depression from baseline to 3 months: exploratory secondary analyses post intervention

ControlInterventionMean difference95% CIp Value
Baseline
n=17
Δ 3 months
n=15
Baseline
n=17
Δ 3 months
n=15
ΔESS (/24)12 (8 to 16)−1* (−6 to 1)12 (8 to 16)−4* (−7 to −3)−2.1−4.72 to 0.480.11
ΔSRI-RC50 (36 to 59)9.4 (−12.5 to 18.8)56 (45 to 72)12.5* (3.1 to 31.3)12.5†−2.53 to 27.430.01†
ΔSRI-PF45 (38 to 56)0 (−8.3 to 8.3)58 (38 to 75)8.3* (0 to 12.5)10.9−0.38 to 22.270.058
ΔSRI-AS43 (34 to 66)0.5 (−14.3 to 14.3)50 (41 to 68)7.1 (−10.7 to 25.0)10.2−5.91 to 26.380.21
ΔSRI-SR66 (46 to 73)8.3 (0 to 16.7)79 (60 to 92)0 (−8.3 to 8.3)−0.10−14.37 to 14.180.99
ΔSRI-AX40 (30 to 65)5.0 (−5.0 to 5.0)70 (43 to 78)15.0 (−5.0 to 30)16.6†0.42 to 33.060.045†
ΔSRI-WB56 (44 to 75)8.3 (−8.3 to 11.8)63 (42 to 71)5.6 (−5.6 to 20.1)8.7−3.52 to 20.940.16
ΔSRI-SF60 (30 to 73)6.3 (−6.3 to 15.6)75 (52 to 86)3.1 (0 to 12.5)4.6−10.31 to 19.50.53
ΔSRI_SS54 (36 to 71)4.4 (−2.4 to 8.9)65 (49 to 70)7.2* (2.8 to 16.7)8.2−1.15 to 17.610.08
ΔHAD-anxiety10 (4 to 12)0 (−4 to 2)6 (3 to 10)−6 (−5 to −2)−1.05−3.96 to 1.860.46
ΔHAD-depression7 (3 to 12)−1* (−2 to −1)5 (3 to 9)−3* (−4 to −1)−1.1−2.83 to 0.630.20
ΔHAD total13 (10 to 24)−1 (−6 to 1)12 (7 to 18)−6 (−9 to 3)−1.8−6.29 to 2.610.40
  • Missing data at 3 months: control n=2, intervention n=2.

  • *Significant intragroup difference from baseline, p<0.05.

  •  † Parameters with significant difference between groups from baseline to 3 months in p value column, p<0.05.

  • AF, attendant symptoms and sleep; AX, anxiety; ESS, Epworth Sleepiness Score; HAD, hospital anxiety and depressions scale; PF, physical functioning; RC, respiratory complaints; SF, social functioning; SR, social relationships; SRI, severe respiratory insufficiency score; SS, sum score; WB, psychological well-being.